{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:08:43Z","timestamp":1750392523448,"version":"3.41.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.medj.2025.100625","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T14:36:46Z","timestamp":1749825406000},"page":"100625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Point of view: Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors"],"prefix":"10.1016","volume":"6","author":[{"given":"Fabio","family":"Conforti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"De Pas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100625_bib1","doi-asserted-by":"crossref","first-page":"100612-1","DOI":"10.1016\/j.medj.2025.100612","article-title":"Genomic landscape and molecularly-informed therapy in thymic carcinoma and other advanced thymic epithelial tumors","volume":"6","author":"M\u00f6hrmann","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.medj.2025.100625_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102014","article-title":"Thymic epithelial tumors: From biology to treatment","volume":"86","author":"Conforti","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.medj.2025.100625_bib3","unstructured":"National Comprehensive Cancer Network. Thymomas and Thymic Carcinomas. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thymic.pdf."},{"key":"10.1016\/j.medj.2025.100625_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2025.100625_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2022.07.009","article-title":"Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group","volume":"174","author":"Antonarelli","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.medj.2025.100625_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107557","article-title":"Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial","volume":"191","author":"Niho","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.medj.2025.100625_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2025.100625_bib8","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial","volume":"37","author":"Cho","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100625_bib9","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(22)00542-3","article-title":"Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Conforti","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2025.100625_bib10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The Integrated Genomic Landscape of Thymic Epithelial Tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025000522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025000522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T14:46:27Z","timestamp":1750344387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025000522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2666634025000522"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100625","relation":{},"ISSN":["2666-6340"],"issn-type":[{"type":"print","value":"2666-6340"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Point of view: Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100612","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100625"}}